4.8 Article

Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

期刊

BMC MEDICINE
卷 20, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12916-022-02526-7

关键词

Atrial fibrillation; Integrated management; Outcomes; Clinical complexity

资金

  1. Abbott Vascular Int
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol Myers Squibb
  8. Pfizer Alliance
  9. Alliance Daiichi Sankyo Europe GmbH
  10. Eli Lilly and Company
  11. Edwards
  12. Gedeon Richter Plc.
  13. Menarini Int. Op.
  14. MSD-Merck Co.
  15. Novartis Pharma AG
  16. ResMed
  17. Sanofi
  18. SERVIER
  19. Vifor

向作者/读者索取更多资源

Adherence to the ABC pathway reduces the risk of major outcomes in clinically complex AF patients, including all-cause death and major adverse cardiovascular events. Ensuring adherence to the ABC pathway is essential to improve clinical outcomes among these patients.
Background Clinical complexity is increasingly prevalent among patients with atrial fibrillation (AF). The 'Atrial fibrillation Better Care' (ABC) pathway approach has been proposed to streamline a more holistic and integrated approach to AF care; however, there are limited data on its usefulness among clinically complex patients. We aim to determine the impact of ABC pathway in a contemporary cohort of clinically complex AF patients. Methods From the ESC-EHRA EORP-AF General Long-Term Registry, we analysed clinically complex AF patients, defined as the presence of frailty, multimorbidity and/or polypharmacy. A K-medoids cluster analysis was performed to identify different groups of clinical complexity. The impact of an ABC-adherent approach on major outcomes was analysed through Cox-regression analyses and delay of event (DoE) analyses. Results Among 9966 AF patients included, 8289 (83.1%) were clinically complex. Adherence to the ABC pathway in the clinically complex group reduced the risk of all-cause death (adjusted HR [aHR]: 0.72, 95%CI 0.58-0.91), major adverse cardiovascular events (MACEs; aHR: 0.68, 95%CI 0.52-0.87) and composite outcome (aHR: 0.70, 95%CI: 0.58-0.85). Adherence to the ABC pathway was associated with a significant reduction in the risk of death (aHR: 0.74, 95%CI 0.56-0.98) and composite outcome (aHR: 0.76, 95%CI 0.60-0.96) also in the high-complexity cluster; similar trends were observed for MACEs. In DoE analyses, an ABC-adherent approach resulted in significant gains in event-free survival for all the outcomes investigated in clinically complex patients. Based on absolute risk reduction at 1 year of follow-up, the number needed to treat for ABC pathway adherence was 24 for all-cause death, 31 for MACEs and 20 for the composite outcome. Conclusions An ABC-adherent approach reduces the risk of major outcomes in clinically complex AF patients. Ensuring adherence to the ABC pathway is essential to improve clinical outcomes among clinically complex AF patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据